Skip to main content

3 Result(s)

within Shusei Tominaga Remove this filter

and

  1. No Access

    Article

    Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

    A trial was conducted to evaluate the feasibility, efficacy, and safety of biweekly administration of irinotecan, a novel topoisomerase I inhibitor, for patients with metastatic breast cancer (MBC) previously ...

    Hidetoshi Hayashi, Junji Tsurutani, Taro Satoh, Norikazu Masuda… in Breast Cancer (2013)

  2. No Access

    Article

    A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer

    The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patien...

    Takeshi Kato, Hideyuki Mishima, Masakazu Ikenaga… in Cancer Chemotherapy and Pharmacology (2008)

  3. No Access

    Article

    A case of invasive lobular carcinoma of the breast first manifesting with duodenal obstruction

    Lobular carcinoma of the breast presents with various clinical manifestations. Lobular carcinoma comprises about one fifth of cases of ductal carcinoma. Intestinal metastasis is dominant in cases of lobular ca...

    Tetsuro Kobayashi, Kunitaka Shibata, Yasuki Matsuda, Shusei Tominaga… in Breast Cancer (2004)